The stock of BioXcel Therapeutics Inc. (NASDAQ:BTAI) increased by $0.13 on Friday to finish at $4.02, up 3.21 percent. The last five days have seen an average of 910,120 shares of common stock traded. 14 times new highs were reached in the current year, with a fall of -$17.46. The average number of shares traded over the last 20 days was 1,748,990, while the average volume over the last 50 days totaled 3,580,850.
BTAI stock dropped -57.73% since last month. On 08/25/23, the company’s shares reached a one-month low of $3.73. The stock touched a high of $34.12 on 02/09/23, after rallying from a low of $3.82 in 52 weeks. The price of BTAI stock has declined by -81.28% or -$17.46 this year, reaching a new high 14 times. Still, the stock price is down -88.22% from the 52-week high.
Insider Transactions
BTAI stock investors should be aware that BioXcel Therapeutics Inc. (BTAI) stock had its last reported insider trading activity 73 days ago on Jun 16. On Jun 16, CEO and President Mehta Vimal sold 30,000 shares at $20.18 each. This transaction resulted in the insider making $605,501. On Jun 15, Mehta Vimal sold 30,000 shares at a price of US$21.54. After the transaction, the insider now owns 39,903 shares. CEO and President Mehta Vimal had earlier sold 6,500 shares on May 22 for $25.79 a share. The transaction was completed for $167,641.
Valuation Metrics
Beta for the stock is 1.07. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 114.01, the price-to-book (PB) ratio of 20.10.
Financial Health
For the three months ended June 29, BioXcel Therapeutics Inc.’s quick ratio was 3.90, while its current ratio was 4.00, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 16.41, and the total debt to equity ratio is 16.41. As far as profitability goes, gross margin for the trailing twelve months is 94.70% percent. Based on annual data, it had gross profit of $0.35 million and revenue of $0.38 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. BTAI’s return on assets (ROA) during the last 12 months has been -105.30%. There was a -94.00% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -309.10%.
Earnings Surprise
According to BioXcel Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $0.46 million, while revenues rose by 100.0% to $0.21 million. It was predicted that BioXcel Therapeutics Inc.’s quarterly earnings would be -$1.83, but it ended up being -$1.75, beating the consensus by -4.60%. EBITDA was -$52.33 million for the quarter. At the end of BioXcel Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 134.23 million, while its total debt was $97.8 million. Equity owned by shareholders amounts to $29.27 million.
Technical Picture
Here’s a quick look at BioXcel Therapeutics Inc.’s (BTAI) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 20.25%, suggesting the stock is oversold, with a 62.51% historical volatility rate.
The stochastic %K and %D were 4.83% and 4.15% respectively, while the average true range (ATR) was 0.58. Based on the 14-day stochastic reading of 7.13%, the RSI (14) reading is 23.31%. On the 9-day MACD Oscillator, the stock is at -0.12, and the 14-day reading is at -1.07.
Analyst Ratings
BioXcel Therapeutics Inc. (NASDAQ: BTAI) was downgraded by Mizuho to a a Neutral rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned BioXcel Therapeutics Inc. (BTAI) an Overweight rating. BTAI is a stock that is recommended for selling by 0 brokerage firms, while 3 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 5 others recommend it as a buy.
What is BTAI’s price target for the next 12 months?
The current consensus forecast for the stock is between $4.00 and $31.00, with a median target price of $10.50. In analyzing these forecasts, the average price target given by analysts for BioXcel Therapeutics Inc. (BTAI) is $12.63.
